University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Nutrition & Health Sciences Dissertations &
Theses

Nutrition and Health Sciences, Department of

8-2011

Effects of Single Nucleotide Polymorphisms in the Human
Holocarboxylase Synthetase Gene on Catalytic Activity
Shingo Esaki
University of Nebraska-Lincoln, shingoe@huskers.unl.edu

Follow this and additional works at: https://digitalcommons.unl.edu/nutritiondiss
Part of the Dietetics and Clinical Nutrition Commons, and the Molecular, Genetic, and Biochemical
Nutrition Commons

Esaki, Shingo, "Effects of Single Nucleotide Polymorphisms in the Human Holocarboxylase Synthetase
Gene on Catalytic Activity" (2011). Nutrition & Health Sciences Dissertations & Theses. 26.
https://digitalcommons.unl.edu/nutritiondiss/26

This Article is brought to you for free and open access by the Nutrition and Health Sciences, Department of at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Nutrition & Health Sciences
Dissertations & Theses by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

EFFECTS OF SINGLE NUCLEOTIDE
POLYMORPHISMS IN THE HUMAN
HOLOCARBOXYLASE SYNTHETASE GENE ON
CATALYTIC ACTIVITY
By

Shingo Esaki

A THESIS

Presented to the Faculty of
The Graduate College at the University of Nebraska
In Partial Fulfillment of the Requirements
For the Degree of Master of Science

Major: Nutrition

Under supervision of Professor Janos Zempleni

Lincoln, Nebraska

August, 2011

EFFECTS OF SINGLE NUCLEOTIDE
POLYMORPHISMS IN THE HUMAN
HOLOCARBOXYLASE SYNTHETASE GENE ON
CATALYTIC ACTIVITY
Shingo Esaki, M.S
University of Nebraska, 2011

Advisor: Janos Zempleni

Holocarboxylase synthetase (HCS) catalyzes the covalent binding of biotin to
carboxylases and histones in eukaryotic cells. Biotinylated carboxylases play essential
roles in the metabolism of fatty acids, amino acids, and glucose; biotinylated histones
play essential roles in gene regulation and genome stability. HCS null individuals are not
viable whereas HCS deficiency is linked to developmental delays and phenotypes such as
short life span and low stress resistance. Greater than 2,500 single nucleotide
polymorphisms (SNPs) have been reported for HCS, but the biological importance of
these polymorphisms is unknown. We hypothesized that some of these SNPs impair
catalytic activity and that this effect can be overcome by dietary intervention with biotin.
Here, we analyzed the enzyme kinetics of five recombinant HCS variants using a
propionyl-CoA carboxylase surrogate (“p67”) as substrate for biotinylation. Vmax of
variants L216R, V96F and G510R were 6%, 78% and 73%, respectively, of the Vmax in
wild-type HCS. The Km values of the variants V96F and G510R were not significantly
different from wild-type HCS. The activity of L216R was too low to allow for

meaningful analysis of Km. In contrast, the affinity of variant Q699R for biotin was
significantly lower than that of wild type HCS (Km: 1.57 times that of wild type) and its
Vmax could be restored to that of wild-type HCS by biotin supplementation. This is the
first biochemical characterization of catalytic activities of HCS variants. Also, this is the
first report to show that HCS activity can be restored to normal by biotin supplementation.
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INTRODUCTION
Biotin is a water-soluble vitamin involved in many metabolic pathways in
mammals [Camporeale and Zempleni 2006]. It plays important roles in the metabolism
of glucose, amino acids and fatty acids due to its role as a coenzyme in the metabolism of
acetyl-CoA carboxylase 1 and 2 (ACC1 and ACC2), 3-methylcrotonyl-CoA carboxylase
(MCC), pyruvate carboxylase (PC), propionyl-CoA carboxylase (PCC) [Camporeale and
Zempleni 2006; Chew, Sarath et al. 2007]. Biotin is also attached covalently to at least
11 distinct lysine residues in histones H2A, H3 and H4 [Camporeale, Shubert et al. 2004;
Kobza, Camporeale et al. 2005; Chew, Camporeale et al. 2006]. Biotinylation of histones
participates in the cross-talk among various histone modifications and in gene regulation
[Camporeale, Giordano et al. 2006; Chew, Raza et al. 2006; Camporeale, Zempleni et al.
2007; Gralla, Camporeale et al. 2008].
Holocarboxylase synthetase (HCS, EC 6.3.4.10) is an enzyme that catalyzes
biotinylation of the five human biotin-dependent carboxylases mentioned above (ACC1,
ACC2, MCC, PC, and PCC). The following four domains have been identified and
characterized in human HCS: N-terminal domain, central domain, linker domain, and Cterminal domain [Hassan, Moriyama et al. 2009]. Both N- and C-termini of HCS
participate in substrate recognition [Hassan, Moriyama et al. 2009]. The central domain
in HCS contains binding sites for both ATP and biotin [Leon-Del-Rio and Gravel 1994;
1999; Kothapalli, Sarath et al. 2005]. The linker domain might play a role in conferring
the flexibility needed for HCS to interact with a diverse group of substrates for
biotinylation [Hassan, Moriyama et al. 2009].
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A series of mutations have been identified in the HCS gene; these mutations
decrease HCS activity substantially and cause features such as exfoliative dermatitis,
hypoglycemia, ketoacidosis, and reduced histone biotinylation. While the prevalence of
HCS mutations is low in the general population, early diagnosis is critical for a good
prognosis. Mutations that decrease the affinity of HCS for biotin are particularly
responsive to treatment with pharmacological doses of biotin. In addition, greater than
2,500 SNPs have been reported for HCS in public databases. The biological importance
of these polymorphisms is unknown.
This thesis has the following two major goals. (1) To identify HCS SNPs that
affect the catalytic activity of HCS. This aim tests the hypothesis that some, but not all,
SNPs in human HCS decrease enzyme activity. Previous studies revealed that domains
in the N-terminus, ATP-/biotin-binding site (central domain), and C-terminus are
important for HCS activity [Hassan, Moriyama et al. 2009]. From each of these three
domains, one to two known SNPs were selected that were likely to affect catalytic
activity. Candidate SNPs were those suspected to cause HCS conformational changes,
e.g., substitution of hydrophobic for basic amino acids. (2) To determine if higher
concentration of biotin could restore substrate biotinylation by HCS variants to the levels
of wild-type HCS. This aim tests the hypothesis that supplementation with biotin
increases the catalytic activity of HCS variants to levels seen with wild-type HCS. These
supplementation studies lay the groundwork for future dietary intervention studies.
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LITERATURE REVIEW

I. Biotin

Biotin, also known as vitamin B7 or H, is an essential water-soluble vitamin
involved in many metabolic pathways in mammals [Zempleni 2005]. Chemically, biotin
is a monocarboxylic acid consisting of a ureido group, thiophane heterocyclic ring, and a
valeric acid side chain [Zempleni 2001; Zempleni 2005; Hassan and Zempleni 2006] (Fig.
1).

Figure 1. Biotin structure

Biotin is a coenzyme in carboxyl transfer reactions from microbes to animals
and plants. Biotin was first discovered by Kögl and Tönnis in 1934 while studying the
growth requirements of yeast in synthetic media [Kogl and Tonnis 1932]. Mammals are
auxotrophic for biotin and obtain it through dietary sources and from intestinal bacteria
that can produce biotin de novo [Wakil, Stoops et al. 1983], or endogenously recover it
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from pre-existing carboxylases. Biotin can be found in high concentration in egg yolk,
cow milk, liver and some vegetables [Said 2009]. For absorption of dietary biotin, the
protein-bound biotin in foods has to be converted to free biotin by the action of
gastrointestinal proteases, peptidases, and biotinidase [Zempleni 2005; Said 2009]. The
adequate intake (AI) of biotin for adults is 30 µg /day.
The following four proteins play major roles in the homeostasis of biotin in
humans (Fig. 2): the sodium-dependent multi-vitamin transporter (SMVT),
monocarboxylate transporter 1 (MCT1), biotinidase (BTD) and holocarboxylase
synthetase (HCS). In most mammalian tissues the primary transport protein of biotin is
SMVT, which also transports pantothenic acid and lipoate [Wang, Huang et al. 1999;
Said 2009]. MCT1 has been reported to participate in the transport of biotin, but its
function is restricted to lymphoid cells [Zempleni and Mock 1999; Daberkow, White et
al. 2003]. In mammals, biotin reutilization occurs through the action of BTD, a specific
amidolyase which hydrolyzes biotin from biotinyl-lysine (biocytin) or short peptides
containing biotin which are the products of normal proteolytic digestion of
holocarboxylases [Wolf, Grier et al. 1985]. BTD is also required for the release of
dietary protein-bound biotin.
Within the cell, the most extensively characterised and understood function for
biotin is to serve as a cofactor for biotin-dependent carboxylases (propionyl-CoA
carboxylase (PCC), cytoplasmatic acetyl-CoA carboxylase 1 (ACC1), mitochondrial
acetyl-CoA carboxylase 2 (ACC2), pyruvate carboxylase (PC) and 3-methylcrotonylCoA carboxylase (MCC)) where it is required for the transfer of carbon dioxide from
bicarbonate to organic acid metabolites and plays important roles in the metabolism
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Figure 2. Biotin transport and metabolism. B: biotin, SMVT: sodium multivitamin
transporter, MCT1: monocarboxylate transporter 1, HCS: holocarboxylase synthetase,
PCC: propionyl-CoA carboxylase, ACC1: cytoplasmatic acetyl-CoA carboxylase α,
ACC2: mitochondrial acetyl-CoA carboxylase β, PC: pyruvate carboxylase, MCC: and 3methylcrotonyl-CoA carboxylase [Figure source: Zempleni, Gralla et al. 2009].

of glucose, amino acids and fatty acids [Wood and Barden 1977; Samols, Thornton et al.
1988; Knowles 1989; Attwood and Wallace 2002]. Biotin is covalently attached to this
family of enzymes by biotin protein ligase (BPL). Biotin-dependent carboxylases have
half-lives of 1–8 days [Majerus and Kilburn 1969; Nakanishi and Numa 1970; Weinberg
and Utter 1979; Weinberg and Utter 1980; Freytag and Utter 1983]. Both ACC1 and
ACC2 catalyze the incorporation of bicarbonate into malonyl-CoA, a key regulatory step
in fatty acid synthesis (ACC1) and mitochondrial fatty acid transport (ACC2). MCC is
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involved in the catabolism of the branched-chain amino acid leucine. PC catalyzes the
carboxylation of pyruvate to produce oxaloacetate in gluconeogenesis. PCC is involved
in the conversion of propionyl-CoA to methylmalonyl-CoA in the metabolism of oddchain fatty acids.

II. Holocarboxylase Synthetase (HCS or HLCS)

The Role of HCS in Humans
HCS is a biotin protein ligase (BPL): an enzyme that catalyzes biotin attachment
onto the biotin-dependent enzymes - carboxylases and histones – in mammalian cells
[Leon-Del-Rio and Gravel 1994; Narang, Dumas et al. 2004]. HCS catalyzes the
biotinylation of the five mammalian biotin-dependent carboxylases mentioned above
(ACC1, ACC2, MCC, PC, and PCC). The covalent bond between the lysine residue of
the carboxylases and biotin occurs in a two-step ATP-dependent reaction [Dakshinamurti
and Chauhan 1994]. In the first step, biotinyl 5’-AMP (B-AMP) is generated; in the
second step, biotin is transferred from B-AMP to the lysine residue in the
apocarboxylases [Narang, Dumas et al. 2004] (Fig. 3).
In addition, in response to changes in biotin availability, HCS has been
demonstrated to function in regulating transcription of the gene that encodes HCS itself
as well as those that code for propionyl-CoA carboxylase, pyruvate carboxylase, acetylCoA carboxylase 1, and the sodium-dependent multivitamin transporter [Dakshinamurti
and Cheah-Tan 1968; Chauhan and Dakshinamurti 1991]. This transcriptional regulatory
process is associated with the soluble guanylyl cyclase signal transduction pathway
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[Solorzano-Vargas, Pacheco-Alvarez et al. 2002]. It has also been suggested that HCS
exerts its transcriptional regulatory role by catalyzing biotin linkage to histones
[Zempleni 2005] (Fig. 4).

Figure 3. Biotin metabolism in Homo sapiens. Btd: biotinidase; HLCS:
holocarboxylase synthetase; apocarboxylase: unbiotinylated carboxylase;
holocarboxylase: biotinylated carboxylase (Figure source: QIAGEN; Valencia, CA)

The carboxylases mentioned above are essential for cellular biosynthesis.
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Therefore, defects in HCS, which reduce the biotin-dependent enzyme activity, affect
several important metabolic processes, including fatty acid synthesis, gluconeogenesis,
and amino acid catabolism.

Figure 4. HCS function in metabolism and transcription regulation. The enzyme
utilizes substrates biotin and ATP to catalyze synthesis of bio- 5′-AMP. The HCS
·intermediate complex interacts with carboxylases to transfer biotin or functions in
transcription, perhaps through histone biotinylation [Figure Source: Ingaramo and
Beckett 2009].
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HCS Structure and Domains
Holocarboxylase synthetase (HCS or HCS, EC 6.34.10) is encoded by an 14-exon
gene, HCS, located on chromosome 21q22.1 [Suzuki, Aoki et al. 1994].

The open

reading frame of full-length HCS encodes 726 amino acids (2181bp) [Suzuki, Aoki et al.
1994]. The existence of at least three splicing variants (76, 82, and 86 kDa) has been
confirmed [Hiratsuka, Sakamoto et al. 1998]. HCS has been detected in cytoplasm,
mitochondria, cell nuclei, and the nuclear lamina [Hiratsuka, Sakamoto et al. 1998;
Narang, Dumas et al. 2004].
The following four domains have been identified and characterized in human
HCS: N-terminal domain, central domain, linker domain, and C-terminal domain [Hassan,
Moriyama et al. 2009] (Fig. 5). Both N- and C-termini of HCS participate in substrate
recognition [Hassan, Moriyama et al. 2009]. The central domain in HCS contains
binding sites for both ATP and biotin [Leon-Del-Rio and Gravel 1994; Chapman-Smith
and Cronan 1999; Kothapalli, Sarath et al. 2005]. The linker domain might play a role in
conferring the flexibility needed for HCS to interact with a diverse group of substrates for
biotinylation [Hassan, Moriyama et al. 2009].
The protein HCS has a homologous region (aa 448-701) to BirA, the biotin apocarboxyl carrier protein ligase of Escherichia coli [Suzuki, Aoki et al. 1994]. BirA ligase
participates in the biotinylation of biotinoyl carboxyl carrier protein (BCCP) and its
amino acid sequence is 21% identical with HCS [Chauhan and Dakshinamurti 1986;
Bankson, Martin et al. 1987; Hymes and Wolf 1999; Hymes, Stanley et al. 2001].

10

Figure 5. Four domains in human HCS: N-terminal domain (M1-F446); central domain
“CD” (F471-S575) containing biotin transfer and ATP-binding sites; linker domain “L”
(T610-V668); and C-terminal domain “CT” (H669-R718). The domains are drawn to scale
[Figure source: Hassan, Moriyama et al. 2009].

HCS Deficiency
Multiple carboxylase deficiency (MCD) is a rare autosomal recessive metabolic
disease caused by defects of enzymes, either biotinidase (biotinidase deficiency, OMIM
#253260) or holocarboxylase synthetase (HCS deficiency, OMIM 253270), in the biotin
cycle [Sherwood, Saunders et al. 1982; Sweetman, Burri et al. 1985].

Patients with

MCD present in the neonatal period or early infancy with metabolic acidosis,
hyperammonemia, tachypnea, skin rash, feeding problems, hypotonia, seizures,
developmental delay, alopecia, and coma [Tammachote, Janklat et al. 2010]. Diagnosis
is suggested by urine organic acids analysis and confirmed by holocarboxylase synthetase
enzyme assay or DNA mutation analysis [Tammachote, Janklat et al. 2010]. As little as
10 milligrams per day of oral biotin usually improve clinical symptoms [Suormala,
Fowler et al. 1997; Wolf 2001]. Patients with HCS deficiency usually have the neonatal
or early-onset form, which may be fatal even within hours of birth [Sweetman, Nyhan et
al. 1982], while patients with biotinidase deficiency have the juvenile or lateonset form.
However, the age of onset and phenotypes are highly variable. Reliable diagnosis of
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either MCD types therefore requires enzyme activity or genetic analysis [Tammachote,
Janklat et al. 2010].

Mutations and SNPs in HCS
A series of mutations have been identified in the HCS gene [Dupuis, Leon-DelRio et al. 1996; Yang, Aoki et al. 2001; Suzuki, Yang et al. 2005]; these mutations
decrease HCS activity substantially and cause features such as exfoliative dermatitis,
hypoglycemia, ketoacidosis, and reduced histone biotinylation [Balnave 1977; Wolf,
Heard et al. 1985; Baumgartner and Suormala 1999; Kobza, Camporeale et al. 2005;
Atamna, Newberry et al. 2007]. While the prevalence of HCS mutations is low in the
general population [Suzuki, Yang et al. 2005], early diagnosis is critical for a good
prognosis. Mutations that decrease the affinity of HCS for biotin are particularly
responsive to treatment with pharmacological doses of biotin [Suzuki, Yang et al. 2005].
To date, there are at least 24 mutations reported in HCS (http://www.hgmd.cf.ac.uk,
accessed June 2011).
In addition, greater than 2,500 SNPs have been reported for HCS in public
databases (http://www.genecards.org/cgibin/carddisp.pl?gene=HLCS&snp=2572&rf=/
home/genecards/current/website/carddisp.pl#snp, accessed May 2011). The biological
importance of these polymorphisms is unknown.

HCS Catalytic Activity Assay in vitro
Bioactivity of HCS has been probed in vitro using p67, a propionyl CoA
carboxylase (PCC)-based polypeptide and a well-established HCS substrate [Lamhonwah,
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Quan et al. 1987; Leon-Del-Rio and Gravel 1994; Campeau and Gravel 2001] which
comprises the 67 C-terminal amino acids in human PCC and contains the consensus
MKM motif for biotin bimding [Lamhonwah, Quan et al. 1987; Campeau and Gravel
2001].

The Km Mutant Theory of HCS
Burri et al. characterized HCS activity in cultured cells from seven patients with
considerable differences in disease severity [Burri, Sweetman et al. 1985]. They showed
that the Vmax values of patients' HCS were lower than the normal mean and were similar
in all except one patient, and that the Km values for biotin were elevated to various
degrees. From their clinical and kinetic observations, they concluded that onset of the
disease and its responsiveness to biotin administration is governed by the degree of
abnormality in the Km of HCS. Suormala et al. investigated the effects of biotin
concentration on carboxylase activities in fibroblasts in five HCS-deficient patients
[Suormala, Fowler et al. 1997]. The carboxylase activities of all patients normalized
when the biotin concentration was increased to 10,000 nM. In carboxylase reactivation
studies, although the kinetics of PCC activation varied greatly, all cells restored their
PCC activity to the normal or nearly normal level (>87%). Reactivation of PCC activity
in relation to time and biotin concentration correlated well with the severity and age at
onset of the illness in four patients. These results were consistent with the original Km
mutant theory proposed by Burri et al. [Burri, Sweetman et al. 1985].
An expression study demonstrated that the Km of the Val550Met HCS mutant was
higher than, but the Km of the Leu237Pro-mutant was the same as, that of the wild-type
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enzyme [Aoki, Suzuki et al. 1997]. Thus, Sakamoto et al. questioned whether the Km
mutant theory could be applied to all patients with HCS deficiency, and proposed that not
only the Km of HCS for biotin, but also the Vmax was an important factor in determining
the severity of symptoms and their responsiveness to biotin therapy [Aoki, Suzuki et al.
1997].
The Km values for biotin of the Gly581Ser and delThr610 mutant proteins were
45 and 3 times higher, respectively, than the wild-type value [Sakamoto, Suzuki et al.
1999]. Previous studies [Aoki, Suzuki et al. 1997] suggested that mutations within the
homologous region (aa 448-701) to BirA result in elevated Km values (Km mutants). The
mutations Arg183Pro, Leu216Arg, Leu237Pro, Val333Glu, and Val363Asp were located
outside the homologous region (non- Km mutants). The Km values of these mutants
differed only slightly from that of the wild type, whereas the Vmax values were extremely
lower than that of the wild type [Sakamoto, Suzuki et al. 1999]. The result suggested that
non- Km mutants can be a cause of biotin responsive HCS deficiency, thereby their
hypothesis was confirmed [Aoki, Suzuki et al. 1997].

Vmax Mutants of HCS
The Vmax mutants group of mutations, namely Arg183Pro, Leu216Arg and
Leu237Pro, map outside of the conserved catalytic core of HCS to the N-terminal region.
Patients with these mutant HCS alleles vary in their responsiveness to biotin treatment.
Although the N-terminal region has been implicated in catalysis [Campeau and Gravel
2001], the precise role played by this extension is poorly understood. These mutations
have provided an insight into the structure and function relationships of HCS.

14

Interestingly, alignment of the BPL sequences from human, dog, horse, mouse, rat,
chicken, Danio and Fugu show that the N-terminal extension is conserved amongst these
vertebrate species. Furthermore, the equivalent amino acids at the above positions are
invariant between these species, again highlighting their importance [Pendini, Bailey et al.
2008].

The Importance of HCS N-terminal Domain for its Catalytic Activity
The importance of the domain of HCS outside the homologous region (aa 448701) to BirA for enzymatic activity was examined in the expression study with HCS
deletion mutants by Hiratsuka et al. [Hiratsuka, Sakamoto et al. 1998]. The N-terminal
amino acid region up to Ile117 had a much less effect on the activity than the amino acid
sequence starting between Ile117 and Met234.

The Physiologic Biotin Concentration and HCS Catalytic Activity
The physiologic biotin concentration of human serum was estimated to be 1-3 nM
and that of liver 0.5-4 nM [Baker 1985]. More recently, the serum biotin level was
estimated to be about 0.24 nM [Mock, Lankford et al. 1995]. These concentrations are
lower than the Km values of wild-type HCS that were measured in cultured fibroblasts
[Burri, Sweetman et al. 1985; Suzuki, Aoki et al. 1996] or lymphoblasts [Burri,
Sweetman et al. 1985], using CCP or PCC as a substrate. Therefore, the mutant HCS
proteins harboring the Leu216Arg, Arg183Pro, Leu237Pro, Val333Glu, or Val363Asp
would not show full activity in the physiologic state. Biotin treatment increases the
biotin concentration in serum up to several hundred nanomolars [Burri, Sweetman et al.
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1985; Suormala, Fowler et al. 1997], thereby helping to increase the velocity of
biotinylation in the cells.

The Difference in the Mechanism of Biotin Attachment to Carboxylases and
Histones
HCS was found to be a constituent of nuclei, in addition to the cytoplasm of cells,
suggesting that HCS could be responsible for biotinylating histones in vivo [Cronan
2001]. However, as histones do not contain the biotin binding motif as seen in
carboxylases, the mechanism and specificity of biotin attachment to histones might be
expected to be significantly different [Healy, McDonald et al.].

III. Biotinidase (BTD)

Biotinidase belongs to the nitrilase superfamily of enzymes, which consists of 12
families of amidases, N-acyltransferases and nitrilases [Brenner 2002]. Some members
of the nitrilase superfamily (vanins-1, -2 and -3) share significant sequence similarities
with BTD [Maras, Barra et al. 1999]. Human BTD gene localizes to chromosome 3p25
and its structure has been determined [Cole Knight, Reynolds et al. 1998]. The human
BTD gene contains four exons: A125-44, B45-309, C310-459 and D460-1961, and they span at
least 44 kb and encode a protein of 543 amino acids [Stanley, Hymes et al. 2004]. The
mature enzyme is encoded by exons B through D. The coding region of BTD has two inframe start codons, both of which might initiate translation [Stanley, Hymes et al. 2004].
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The cellular distribution of BTD is controversial. While the existence of BTD
acitivty in microsomes and mitochondria is accepted universally [Pispa 1965; Garganta
and Wolf 1990; Nilsson and Ronge 1992], the presence of BTD in nuclei is less certain
[Zempleni, Hassan et al. 2008].
The classical role of BTD in metabolism is to hydrolyze biocytin (biotinyl- ε lysine) generated in the breakdown of biotin-dependent carboxylases [Hymes,
Fleischhauer et al. 1995]. Thus, free biotin is released and recycled in holocarboxylase
synthesis and used in other processes [Camporeale and Zempleni 2006]. The role of
BDT in biotinylation of histones has been demonstrated based on in vitro studies with
purified histones [Hymes, Fleischhauer et al. 1995]. It was proposed that BTD might
mediate the binding of biotin to histones by the hydrolysis of biocytin forming a biotinylthioester intermediate (cysteine-bound biotin) near its active site. Thus, biotin is bound to
the biotinyl moiety from the cysteine residue and transfer to the ε-amino group of the
lysine in histones [Hymes, Fleischhauer et al. 1995; Hymes and Wolf 1999]. The Km
value for hydrolysis of biocytin by biotinidase is in the micromolar range and hydrolysis
occurs optimally at pH 5.5–6, with a precipitous decrease in activity above pH 7. On the
other hand, biotinylation of histones by biotinidase occurs at physiological pH and
concentrations of biocytin (nanomolar range) [Hymes, Fleischhauer et al. 1995].
Evidence has been provided that BTD might catalyze debiotinylation of histones
[Ballard, Wolff et al. 2002]. It was proposed that variables such as microenviroment in
chromatin, posttranscriptional modifications and alternative splicing might determine
whether BTD acts as a biotinyl histone transferase or histone debiotinylase [Zempleni
2005]. For example covalent modifications such as glycosylation might influence the
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enzyme activity to biotinylate or debiotinylate histones [Cole, Reynolds et al. 1994;
Ballard, Wolff et al. 2002]. In the same way, the presence of cofactors such as high
concentrations of biocytin might favor and increase the rate of biotinylation of histones
[Ballard, Wolff et al. 2002].

IV. Histone Biotinylation

Hisotnes and Chromatin
Histones are small basic proteins (11-22 kDa) involved in the folding of the DNA
into chromatin. They are modified by the covalently binding of biotin to lysine residues
by holocarboxylase synthetase [Wolffe 1998; Stanley, Griffin et al. 2001]. There are five
major classes of histones in chromatin: H1, H2A, H2B, H3 and H4 [Wolffe 1998].
Histones H2A, H2B, H3 and H4 form an octamer of core histones with one H3-H3-H4H4 tetramer and two H2A-H2B dimers while histone H1 is the linker histone bound to
the DNA in between two nucleosomes (Fig. 6) [Kothapalli, Camporeale et al. 2005].
Importantly, histones are positively charged proteins due to the presence of a large
number of lysine and arginine residues (20-25% of the amino acids). The electrostatic
interaction between the negative charge of DNA and the positive charge of histones
stabilizes the formation of the nucleosomal core particle [Wolffe 1998].
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Figure 6. Nucleosome structure. Histone H1 and octamer.

Covalent Histone Modifications
Histones are target for reversible covalent modifications such as acetylation,
methylation, phosporylation, poly (ADP-ribosylation) and biotinylation. These
modifications have distinct functions in gene expression, chromatin remodeling,
transcriptional regulation, and DNA repair [Turner 2000; Moore and Krebs 2004; Narang,
Dumas et al. 2004; Khan and Krishnamurthy 2005]. For example, acetylation of lysine
residues has been associated with transcriptional activity of genes [Bannister, Schneider
et al. 2002]. Methylation may be associated with transcriptional activation or repression.
Phosphorylation and poly (ADP-ribosylation) are associated with signaling and DNA
repair [Peters, Griffin et al. 2002].
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Histone Biotinylation
In previous studies, 11 biotinylation sites in histones have been identified: K9,
K13, K125, K127 and K129 in histone H2A [Chew, Camporeale et al. 2006]; K4, K9,
K18 and perhaps K23 in histone H3 [Kobza, Sarath et al. 2008]; and K8 and K12 in
histone H4 [Camporeale, Shubert et al. 2004] (Fig. 7 [Ho and Zempleni 2009]).

Figure 7. Modification marks in histones H2A, H3, and H4 ([Figure source: Ho and
Zempleni 2009]). Abbreviations: Ac, acetate; B, biotin; M, methyl; P, phosphate; U,
ubiquitin [Jenuwein and Allis 2001; Fischle, Wang et al. 2003; Camporeale, Shubert et al.
2004; Kobza, Camporeale et al. 2005; Chew, Camporeale et al. 2006; Chew, Raza et al.
2006; Kouzarides and Berger 2007; Kobza, Sarath et al. 2008]. Marks labeled with “?”
are based on preliminary observations and await confirmation [Camporeale, Shubert et al.
2004; Chew, Raza et al. 2006].
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Biotinylation of histones plays an important role in the cellular response to DNA
damage [Kothapalli, Sarath et al. 2005], cell proliferation [Stanley, Griffin et al. 2001],
and mitotic condensation of chromatin [Kothapalli and Zempleni 2005]. In fact,
H4K12bio has been associated with gene silencing [Camporeale, Oommen et al. 2007]
and repression of transponsable elements [Chew, West et al. 2008].

The Role of HCS in Biotinylation of Histones
The important role of HCS in biotinylation of histones has been confirmed in
various studies [Leon-Del-Rio, Leclerc et al. 1995; Camporeale, Giordano et al. 2006].
Camporeale et al. compared the ability of SMVT mutants and HCS-deficient Drosophila
melanogaster to biotinylate histones. The results demonstrated that HCS knockdown is
associated with a decrease in biotinylation of histones due to the low biotin-ligase activity,
rather than the low levels of biotin in the cells [Leon-Del-Rio, Leclerc et al. 1995].
Importantly, Bao et al. recently reported that HCS interacts physically with histone H3 to
mediate binding to chromatin and subsequent biotinylation of K9 and K18 in histone H3
[Bao, Pestinger et al. 2011].
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MATERIALS AND METHODS
Candidate SNPs selection
As of May 7, 2011, 2572 SNPs in HCS gene have been reported on “GeneCards”
website (http://www.genecards.org/cgibin/carddisp.pl?gene=HLCS&snp=2572&rf=/
home/genecards/current/website/carddisp.pl#snp). The SNPs in the coding region of
HCS gene were detected out of these. Candidate SNPs were then limited to those which
cause amino acid changes. Furthermore, candidate SNPs were limited to those which
were suspected to cause HCS conformational changes, e.g., substitution of basic for
hydrophobic amino acid, for further biochemical analysis.

Recombinant HCS
A clone of full-length human HCS was provided by Yoichi Suzuki (Tohoku
University, Sendai, Japan) [18]. EcoRI and XhoI restriction sites were inserted by PCR,
using forward primer 5’-GTCCGAATTCGGGGAAGATAGACTCCACATGGATAAT
G-3’ and reverse primer 5’-ATTTCTCGAGCCCGCCGTTTGGGGAG-3’. The PCR
product was digested with EcoRI and XhoI and cloned into vector pET41a(+) (Novagen,
Madison, WI), fusing glutathione S-transferase (GST), S·tag, and a 6x his·tag to the Nterminus of HCS; this construct also contains a 6x his·tag at the C-terminus of HCS. The
plasmid was named “HCS-pET41a(+)” and codes for a fusion protein of 114.6 kDa; its
identity was verified by sequencing [Bao, Pestinger et al. 2011].
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Site-directed mutagenesis
5 kinds of different SNPs in HCS gene were chosen for further analysis. HCSpET41a(+) was digested with EcoRI and XhoI and subcloned into vector pBluescript II
SK (+) (Stratagene; Wilmington, DE). The plasmid was named “HCS- pBluescript II SK
(+)”. Each mutation was introduced to HCS-pBluescript II SK (+) using GeneTailor™
Site-Directed Mutagenesis System (Invitrogen; Carlsbad, CA). Each plasmid was then
digested with EcoRI and XhoI and subcloned into vector pET41a(+).

Expression and purification of recombinant HCS
ArcticExpress (DE3) Competent Cells (Agilent Technologies; Santa Clara, CA)
transformed with HCS-pET41a(+) [Bao, Pestinger et al. 2011] were cultured in LB Broth
Medium with 20 μg/ml of gentamycin and 50 μg/ml of kanamycin, and incubated
overnight at 37°C. Bacteria were allowed to grow until an OD600 of 0.5- 1.0 was
reached. Protein expression was induced adding Isopropyl-beta-D-thiogalactopyranosid
(IPTG) at a final concentration of 1mM, and incubated at 12ºC for 24 hours. Cells were
centrifuged at 4ºC (3,000 g for 30 minutes) and precipitated cells were resuspended in
PBS with protease inhibitor cocktail (Sigma-Aldrich; St. Louis, MO). Samples were
sonicated on ice (Branson 250 Digital Sonifier, Danbury, CT) three times for 10-second
burst and alternated with 10-second resting periods on ice. The lysate were centrifuged at
10,000 g for 10 minutes at 4ºC. HCS fusion protein were purified by GSTrap™ FF
Columns (GE Healthcare; Piscataway, NJ) on ÄKTA™ protein purification system (GE
Healthcare). HCS in column fraction were identified by gel electrophoresis followed by
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coomassie blue staining and western blot using an antibody to the C-terminus in human
HCS.

Expression and purification of recombinant p67

The polypeptide p67 is frequently used to confirm biological activity of HCS. It
is the C-terminal 67 amino acid biotin carboxyl carrier (BCC) domain of the propionylCoA carboxylase (PCC) α subunit (Leu637-Glu703). Rosetta™ 2(DE3) Competent Cells
(EMD Chemicals; Gibbstown, NJ) transformed with p67- pET30 [Kobza, Sarath et al.
2008] were cultured in LB Broth Medium with 15 μl of kanamacyn, and incubated
overnight at 37°C. Cells were allowed to grow until an OD600 of 0.5 - 0.6 was reached.
p67 expression was induced by IPTG 1 mM final concentration and incubated for 16
hours at 37ºC. After incubation, samples were centrifugated at 3,000 g for 30 minutes
and purified using His Trap FF Columns (GE Healthcare) on an ÄKTA™ protein
purification system (GE Healthcare). Because BirA ligase in Escherichia coli is known
to biotinylate some of the recombinant p67, the biotinylated fraction of p67 was removed
using avidin columns.

Normalization of the HCS constructs

Purified proteins of wild-type HCS and its variants were mixed with NuPAGE®
LDS Sample Buffer (4X) (Invitrogen), boiled at 95 ºC for 10 minutes, and loaded into
NuPAGE® Novex 4-12% Bis-Tris Gel (Invitrogen). Relative concentrations of each
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recombinant HCS (rHCS) construct were normalized by staining with coomassie blue
and by western blot using an antibody to the C-terminus in human HCS.

HCS catalytic activity assay using p67 as substrate
Bioactivity of the purified HCS (50 nM) was measured using 50 μl of a mix
containing 75 mM Tris- Acetate (pH 7.5), 7.5 mM ATP, 0.3 mM dithiothreitol (DTT), 45
mM MgCl2, 45 μM p67 and graded concentration of biotin (0, 1, 3, 6, 12 and 24 μM).
The mix was incubated at 37 ºC for 3 hours. 50 μl of tricine loading buffer was added to
the mix. The mix (100 μl) was boiled at 95 ºC for 10 minutes. 15 μl of the sample was
loaded and run on a 16% tricine gel. The gel was transferred onto the PVDF membrane.
The membrane was dipped in PBS to remove traces of transfer buffer, incubated with
Odyssey blocking buffer (Licor; Lincoln, NE) at room temperature for 1 hour, and
washed with 0.1% T-PBS (PBS containing 0.1% Tween 20) at room temperature 3 times
- 5 minutes each - with gentle rotation. The membrane was then transferred to a black
tray containing 2.5 µL of the stock solution of IRDye 800CW Streptavidin (Licor; 2.4
moles of IRDye 800 CW/1 mole of streptavidin) in 20 mL of 0.1% TPBS and incubated
for 1 hour at room temperature. The membrane was washed with 0.1% TPBS containing
5 M NaCl at room temperature 4 times - 5 minutes each - with gentle rotation. The
membrane was scanned to detect the probed p67-bound biotin by measuring infrared
absorbance of IRDye 800CW Streptavidin at 800 nm (channel 800CW) in the Odyssey
imaging system. Non-linear regression analysis was used to calculate Km and Vmax of
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HCS for biotin using the software “GraphPad Prism 5.00” (GraphPad Software; La Jolla,
CA).

Statistical Analysis
Homogeneous variances were identified by using Bartlett’s test. Significance of
differences was tested by one-way ANOVA. Fisher’s Protected Least Significant
Difference procedure was used for posthoc testing. StatView 5.0.1 (SAS Institute; Cary,
NC) was used to perform all calculations. Differences were considered significant if P <
0.05. Data were expressed as mean ± SD.

RESULTS

Bioinformatics
It turned out that there are 14 HCS variants overall in the coding region of HCS in
GeneCards database. 6 variants of them do not cause amino acid changes (group 1). 4
variants of them cause amino acid changes, but the side chains have exactly the same
characteristics before and after the substitutions (group 2): the substitution of aspartate
for glutamate (both have hydrophilic and negatively charged R groups), the substitution
of histidine for arginine (both have hydrophilic and positively charged R groups) and the
substitution of leucine or isoleucine for valine (SNP ID: rs61731502; both have
hydrophobic R groups). The rest 4 variants cause amino acid substitutions by which the
characteristics of the side chains also change (group 3). The variant rs61732502
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substitutes phenylalanine (hydrophobic and aromatic R groups) for valine (hydrophobic
and aliphatic R groups), the variant rs28934602 substitutes arginine (hydrophilic and
positively charged R groups) for leucine (hydrophobic and neutral R groups), the variant
rs75867009 substitutes arginine for glycine (hydrophobic and positively charged R
groups) and the variant rs79373682 substitutes arginine for glutamine (hydrophobic and
positively charged R groups).
The 5 variants below – one from group 2 and all four variants from group 3 - were
chosen for further catalytic analysis (Table 1).

Table 1. HCS variants
SNP ID

nucleotide
substitution

amino acid
substitution

rs61732502

G286T

V96F

rs61732502

G286C

V96L

rs28934602

T647G

L216R

rs75867009

G1528A

G510R

rs79373682

A2096G

Q699R

amino acid side chains' characteristics



HCS
domain

Both are hydrophobic.
aliphatic → aromatic

N-terminal

Both are hydrophobic.

N-terminal

hydrophobic and neutral → hydrophilic and
basic (positively charged)

N-terminal





neutral → basic (positively charged)
Both are hydrophilic.
Arginine is much bulkier than
Glycine.

central




neutral → basic (positively charged)
Both are hydrophilic.

C-terminal

Recombinant HCS and p67
After recombinant proteins of wild-type HCS and the variants shown above were
produced, relative concentrations of each recombinant HCS (rHCS) construct were
normalized by staining with coomassie blue (Fig. 8 (a)) and by western blot using an
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antibody to the C-terminus in human HCS (Fig. 8 (b)). Recombinant p67 is biotinylated
by BirA in E. coli and therefore requires affinity purification before use. When
recombinant p67 was purified by using avidin columns, the vast majority of biotinylated
p67 was removed. For all assays described below, biotin-depleted p67 was used.

1

2

3

4

5

(a)

6
← rHCS 115 kD

1 2 3 4 5 6

(b)
← rHCS 115 kD

Figure 8. Normalization of rHLCS concentrations for enzyme kinetics studies.
Wild-type HLCS (WT) and variants were stained with coomassie blue (panel a) and
probed with anti-HLCS (panel b). 1: WT, 2: V96F, 3: V96L, 4: L216R, 5: G510R, 6:
Q699R.

28

Dose-response studies in HCS catalytic activity assay using p67 as substrate
A titration of wild-type rHCS was conducted with overabundant amount of p67
(45 µM) and biotin (100 µM) to determine a concentration where enzyme concentration
is proportional to the amount of substrate biotinylation when substrate and coenzyme
availability are not limiting factors in this HCS catalytic assay. The amount of
biotinylated p67 in this assay increased linearly up to a concentration of rHCS of 60 nM,
and leveled off thereafter. Subsequent experiments were conducted using 50 nM HCS to
ensure assay linearity.
Then p67 was titrated with an overabundant amount of biotin (100 µM) to
determine a concentration where substrate availability is no longer a limiting factor in
this assay. A linear dose-response was obtained for up to 20 μM p67, while p67 was no
longer rate limiting beyond that concentration. For subsequent experiments, p67 was
used at a concentration of 45 μM.

Kinetics analysis of p67 biotinylation by wild-type rHCS and its variants
We determined the kinetic properties of the wild-type and five rHCS variants
using p67 as substrate. Table 2, Fig. 9 and Fig. 10 show Km values for biotin and Vmax
values of the rHCS constructs. Note that the activity of L216R was too low to allow for
meaningful analysis of Km. All these Vmax and Km values were homogeneous. Fig. 11
(a) – (e) are the graphs of initial velocity depending on biotin concentration. Three
variants, V96F, V96L and L216R, are within the N-terminal domain (aa1-446). The
variant Gly510Arg is within the central domain (aa471-575). And the variant Q699R is
within the C-terminal domain (aa669-718).
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Three variants, V96F, L216R and G510R, had significantly different Vmax values
compared with that of the wild type. The Vmax values of V96F and G510R variants were
decreased to a slight extent: 78% and 73%, respectively (percentage of the wild-type
value), and the Vmax value of L216R variant was markedly decreased: 6%.
Only the Q699R variant had significantly different Km value compared with that
of the wild type. The Km values of this mutant enzyme for biotin were higher than that of
the wild type by 57%.

Table 2. Vmax and Km values of wild-type rHCS and its variants
Vmax (pmol biotin/(h*pmol HCS) )
Vmax (% wild type)
Km (µM)
Km (fold over wild type)

WT

V96F

V96L

L216R

G510R

Q699R

3.9±0.3
100

3.0±0.5
78

4.1±0.4
106

0.2±0.04
6

2.8±0.5
73

3.9±0.6
101

4.0±1.0

4.0±1.9

5.1±1.4

n.d. *

3.4±1.9

6.3±2.6

1

1

1.27

n.d. *

0.84

1.57

* n.d.=not detectable. The activity of L216R was too low to allow for meaningful analysis of Km.
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5

a

a

Vmax (pmol biotin/h*pmol HCS)

a
4
b

b

3

2

1
c
0
WT

V96F

V96L

L216R G510R Q699R

Figure 9. Vmax values of the wild-type rHCS and its variants. rHCS was incubated
with p67, biotin and cofactors for 3 hours; enzyme activity was measured by infrared
spectroscopy. Bars without a common letter are significantly different (n=3, P<0.05).
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10
b
8

Km (µM)

a, b
a

6

a

a
4

2

0
WT

V96F

V96L

G510R

Q699R

Figure 10. Km values of the wild-type rHCS and its variants. rHCS was incubated
with p67, biotin and cofactors for 3 hours; enzyme activity was measured by infrared
spectroscopy. Note that the activity of L216R was too low to allow for meaningful
analysis of Km. Bars without a common letter are significantly different (n=3, P<0.05).
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Fig 11 (a)-(e). Non-linear regression analysis of HLCS variants V96F (panel a),
V96L (b), L216R (c), G510R (d), and Q699R (e) compared with wild-type HLCS.
Data points were fitted by using the Michaelis-Menten equation (N=3 independent
analyses for each HCS variant). Abbreviations: WT = wild type.

SNPs that affect the catalytic activity of HCS
The variant V96F had 78% Vmax and 100% Km of that of the wild type, suggesting
that this variant’s affinity for biotin was the same level as wild type, and the activity of
this enzyme was compromised by 22% but not restored with higher concentrations of
biotin.
The variant V96L had 106% Vmax and 127% Km of that of the wild type,
suggesting that the affinity for biotin and the activity of this variant were the same level
as wild type statistically.
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The variant L216R had as low as 6% Vmax of that of the wild type (Km value was
not available), suggesting that the activity of this enzyme was compromised by 94% but
not restored with higher concentrations of biotin.
The variant G510R had 73% Vmax and 84% Km of that of the wild type,
suggesting that this variant’s affinity for biotin was the same level as wild type
statistically, and the activity of this enzyme was compromised by 27% but not restored
with higher concentrations of biotin.
The variant Q699R had 101% Vmax and 157% Km of that of the wild type,
suggesting that this variant’s affinity for biotin was lower by 57% than wild type, and the
activity of this enzyme was the same level as wild-type enzyme because it was restored
with higher concentrations of biotin.

The concentration of biotin needed to achieve normal substrate biotinylation by
HCS variants compared with wild-type HCS
Of the 5 variants studied here, V96L variant showed the same affinity for biotin
and the same activity as wild-type enzyme. The activity of the variants V96F, L216R
and G510R was compromised but not restored with higher concentrations of biotin.
In contrast, the affinity of variant Q699R for biotin was significantly lower than
that of wild type HCS (Km: 1.57 times that of wild type) and its Vmax could be restored to
that of wild-type HCS by biotin supplementation (Fig. 11-(e)).
Our knowledge of the intracellular concentrations of biotin in mammalian tissues
is rather limited. Evidence suggests that the concentrations of biotin in liver and kidney
is about 3.3 µmol/kg and 4.5 µmol/kg, respectively, in pigs fed a normal diet containing
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200 µg biotin/kg [Kopinski, 1989]. Likewise, the concentration of biotin is about
500―900 fmol per cell in human embryonic palatal mesenchymal cells in culture
[Takechi, 2008], which translates into a concentration of about 6.8 µmol/L assuming a
cellular volume of 0.3 nL [Nibbering, 1990]. The tissue concentration of free biotin might
be lower than that of protein-bound biotin [Rathman, 2002], but this might be offset by
local accumulation of free biotin in HLCS-rich microdomains. Notwithstanding the
uncertainties with regard to the true concentrations of biotin in human tissues and cellular
compartments, we are reasonably confident that the Km values reported for HCS in this
study are similar to the concentrations of biotin in human tissues. If so, biotin
supplementation might benefit individuals homozygous for the HLCS variant Q699R.

DISCUSSION
The two objectives of this study were (1) to identify HCS SNPs that affect the
catalytic activity of HCS and (2) to determine if higher concentration of biotin could
restore normal substrate biotinylation by HCS variants compared with wild-type HCS.
There have been multiple reported mutations in the HCS gene that give rise to
MCD (reviewed in Bailey et al. 2008 [Pendini, Bailey et al. 2008]; summarized in Table
3). The severity of disease varies greatly with the genotype of each individual. Broadly,
the mutations can be classified into two groups. Firstly the Km mutants are amino acid
substitutions that result in an enzyme with decreased affinity for biotin. Patients bearing
these mutant HCS respond well to oral administration of pharmacological doses of biotin.
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Secondly, the Vmax mutants are substitutions where the activity of the enzyme is
compromised but not restored with higher concentrations of biotin.
According to these mutant theories, V96F, L216R and G510R variants are Vmax
mutants, and Q699R variant is a Km mutant for the variants studied in this thesis. This
observation agrees with the report by Sakamoto et al. [Sakamoto, Suzuki et al. 1999] that
L216R is a Vmax mutant, and with the report that most of the Km mutants lie in the Cterminal catalytic portion of the enzyme [Pendini, Bailey et al. 2008]. To date there are
no reports of an X-ray structure for human HCS, but recent studies reporting new
structures of BPL from bacteria E. coli has provided powerful insights into the HCS
structure.

Table 3. Biochemical characterisation of HCS missense mutations. [Table source:
Bailey et al. 2008]
Mutation
Activity (% wildtype)
Km Biotin (fold over wildtype)
Wildtype
100
1
E42D
120
N.D.
R183P
1.7
0.6
L216R
0.3
1.4
L237P
1.2-4.3
0.4–1.2
V333E
2–10
1.5
R360S
22
N.D.
V363D
3.7
1.1
Y456C
0.2
N.D.
T462I
<10
N.D.
L470S
4.3
N.D.
R508W
34.5
23
V547G
3.4
N.D.
V550M
16.6
6.5
D571N
0.1
N.D.
G581S
<10
44.3
D634Y
12
N.D.
Amino acid substitutions in the catalytic region (residues 422–726) induce a 3–44-fold elevated
Km for biotin compared to wildtype HCS. N.D: Not determined.
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Unlike mutations in the HCS gene, there have been no reports which focused on
SNPs in the HCS gene to date. For a variation to be considered a SNP, it must occur in at
least 1% of the population. SNPs, which make up about 90% of all human genetic
variation, occur every 100 to 300 bases along the 3-billion-base human genome. Many
SNPs have no effect on cell function, but others could predispose people to disease or
influence their response to a drug, etc. This is the first comprehensive study of the
catalytic activity of HCS SNPs.
Of the 5 substitutions studied in this thesis, L216R has already been reported in
the UniProt database (P50747). This allele was first reported as a mutation in the human
HCS gene, and has subsequently appeared to occur at a high frequency in the Samoan
and Cook Island populations [Morrone, Malvagia et al. 2002], which is probably the
reason why this variant was determined as a SNP. As our data in this thesis shows, this
allele results in markedly reduced enzyme activity. According to the report by Morrone
et al., five of the seven homozygous patients with this variant died between age 3 days to
3 years. All patients presented within 24 hours of birth with severe acidosis. The two
babies that did not receive biotin treatment died within seven days. Despite biotin
therapy, three of the patients continued to show severe dermatological symptoms and
recurrent septicaemia followed by metabolic decompensation. All died during one of
these episodes [Morrone, Malvagia et al. 2002]. In contrast, a patient with this variant in
the heterozygous form (L216R /V363D) showed good clinical response to biotin therapy
(10–40 mg/day) [Dupuis, Campeau et al. 1999]. Biotin responsiveness was attributed to
the presence of the biotin-responsive allele V363D. Patients homozygous for the L216R
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variant have since been reported and, their response to biotin therapy has varied for some
reason [Wilson, Myer et al. 2005]. Interestingly, a recent study demonstrated that this
variant induced increased protein turnover thereby providing a partial explanation for the
poor response to biotin therapy [Bailey, Ivanov et al. 2008]. Further crystallographic
studies on the HCS structure will be required to fully understand how mutations distal
from the active site of HCS have an effect on function.
Blast search against PDB databank returned prokaryotic biotin ligase (BirA)
structures alignment to the central and C-terminal domains of the human HCS (alignment
from around residues 460 to 710 aa), with approximately 31% sequence identity. A 3D
modeling would give detailed information about the changed molecular interactions due
to the substitution. However, modeling is only possible for the central and C-terminal
domains (i.e. for G510R and Q699R), for which structural information is available while
no human or eukaryotic biotin ligase structure is available to date.
HCS substitutions G510R and Q699R are located at the equivalent sites in the
bacterial structures, indicating that substitution sites 510 and 699 are not in the biotin
binding site and are located in the solvent exposed exterior of the protein (Fig. 12 and Fig.
13). In the central domain of human HCS, the R508-S515 loop corresponds to one of the
biotin-binding site (R118-S125) in BirA [Hassan, Moriyama et al. 2009]. However,
substitution G510R does not yield any specific hydrogen bond interactions with the cofactor. In contrast, the mutations R508W and N511K have been reported to cause severe
damage to the catalytic activity of HCS [Pendini, Bailey et al. 2008] (Fig. 12) because
these sites are critical residues in the loop covering the ligand-binding site and R508 coordinates to the backbone carbonyl N712 to form a salt bridge, removing this would
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result in a more flexible loop. The residue 510 in HCS is also close to the putative
carboxylase binding site, but this can not be reliably predicted from the E.coli BirA BCCP structure due to very limited structural information and moreover, the human
carboxylases are structurally not very similar to BCCP. Q699R occurs in a turn at the
end of a β-strand and would not drastically change the packing of the molecule as it is in
a solvent exposed loop. These observations suggest that these two variants do not
majorly change the protein structure to affect its function. Thus probably the variants
G510R and Q699R are presumed to be not critical for the protein folding or function.
This inference agree with our kinetics data in this thesis: Vmax values of variants G510R
and Q699R were 73 and 101% of that of the wild type, and Km values were 0.84 and 1.57
times that of the wild type, respectively. These kinetics data suggest that these two
variants do not majorly change the catalytic activity of HCS, whereas Vmax value of
variant L216R was only 6% of the Vmax in wild-type HCS and this variant causes
multiple carboxylase deficiency (MCD) as mentioned above.
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Fig. 12. R508W, N511K and other mutations in the central and C-terminal domains
of HCS [Figure source: Pendini, Bailey et al. 2008]. Residues that are mutated in
multiple carboxylase deficiency (MCD) are highlighted (in red) on the HCS model with
biotinyl-5′-AMP shown in the active site (in stick and ball representation). It can be seen
from this model that these mutations cluster around the biotin and ATP binding sites.
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Fig. 13. Substitution sites 510 and 699 in the central and C-terminal domains of
HCS. The substituted residues (510R and 699R) are highlighted in purple, while the wild
type residues are highlighted in blue. The biotinyl 5’-AMP bound at the active site is
highlighted in cyan. Substitution G510R occurs in one of the biotin-binding site (R508S515 loop). Q699R occurs in a turn at the end of a β-strand. Either substitution site (510
and 699) is not involved in the biotin binding site and is located in the solvent exposed
exterior of the protein.

In summary, Vmax of variants L216R, V96F and G510R variant were 6%, 78%
and 73%, respectively, of the Vmax in wild-type HCS. The Km values of the variants
V96F and G510R were not significantly different from wild-type HCS. The activity of
L216R was too low to allow for meaningful analysis of Km. In contrast, the affinity of
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variant Q699R for biotin was significantly lower than that of wild type HCS (Km: 1.57
times that of wild type) and its Vmax could be restored to that of wild-type HCS by biotin
supplementation. This is the first biochemical characterization of catalytic activities of
HCS variants. Also, this is the first report to show that HCS activity can be restored to
normal by biotin supplementation.
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